Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.54 |
| ▸ | NOS2 | P35228 | 3/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13898488 | 0.82 | NOS2 (0.37) | NOS3NOS2PDPK1 | |
| SCHEMBL17807492 | 0.74 | NOS2 (0.53) | NOS3NOS2MAPK10PDPK1CHRNB4 | |
| SCHEMBL16865684 | 0.71 | NOS2 (0.50) | NOS3NOS2MAPK10PDPK1CHRNB4 | |
| SCHEMBL3307465 | 0.71 | NOS2 (0.61) | NOS3NOS2GRIN2BACHEHTR1A | |
| SCHEMBL8057615 | 0.71 | NOS2 (1.00) | NOS3NOS2 | |
| SCHEMBL163051 | 0.71 | MAPK10 (0.55) | NOS3NOS2MAPK10MAOA | |
| SCHEMBL29384557 | 0.71 | MAPK10 (0.55) | NOS3NOS2MAPK10MAOA | |
| SCHEMBL28565283 | 0.69 | NOS2 (0.59) | NOS3NOS2GRIN2BACHEHTR1A | |
| Hydrochloric Acid SCHEMBL27495714 | 0.69 | MAPK10 (0.54) | NOS3NOS2MAPK10MAOA | |
| SCHEMBL22978809 | 0.68 | NOS2 (0.62) | NOS3NOS2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | NOS3 3723/4885NOS2 3764/4885MAPK10 2395/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | NOS3 3723/4885NOS2 3764/4885MAPK10 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.